KYN-101 - ≥98% , CAS No.2247950-73-6

CAS: 2247950-73-6 Cat. No.: K649692 Peso molecular: 386.42

GRADE & PURITY ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Descripción general

KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.

In Vitro

KYN-101 (0.5, 1 µM; 24 h) decreases the CYP1A1 mRNA expression in IDO high samples. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

KYN-101 (10 mg/kg; p.o.; daily for 12 days) shows anti-cancer activity in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice) Dosage: 10 mg/kg Administration: P.o.; daily for 12 days Result: Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.

Form:Solid

Specifications

Especificaciones y pureza

≥98%

Mecanismos bioquímicos y fisiológicos

KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.

Condiciones de almacenamiento de almacenamiento

Store at -20°C

Enviado en

Ice chest + Ice pads

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Tipo de acción

INHIBITOR

Pureza

≥98%

Nombres e identificadores

• Peso molecular: 386.42

Referencias

1. Yvhao Xie, Xinxin Li, Qingshi Meng, Jinjun Li, Xin Wang, Liying Zhu, Weiwei Wang, Xiaoqiong Li.  (2024)  Interplay between gut microbiota and tryptophan metabolism in type 2 diabetic mice treated with metformin.  Microbiology Spectrum,      [PMID:39162538] [10.1128/spectrum.00291-24]